DeSantis Grace, Liu Junjie, Clark David P, Heine Andreas, Wilson Ian A, Wong Chi-Huey
Department of Chemistry, The Scripps Research Institute, 10550N. Torrey Pines Road, La Jolla, CA 92037, USA.
Bioorg Med Chem. 2003 Jan 2;11(1):43-52. doi: 10.1016/s0968-0896(02)00429-7.
2-Deoxyribose-5-phosphate aldolase (DERA, EC 4.1.2.4) catalyzes the reversible aldol reaction between acetaldehyde and D-glyceraldehyde-3-phosphate to generate D-2-deoxyribose-5-phosphate. It is unique among the aldolases as it catalyzes the reversible asymmetric aldol addition reaction of two aldehydes. In order to expand the substrate scope and stereoselectivity of DERA, structure-based substrate design as well as site-specific mutation has been investigated. Using the 1.05 A crystal structure of DERA in complex with its natural substrate as a guide, five site-directed mutants were designed in order to improve its activity with the unnatural nonphosphorylated substrate, D-2-deoxyribose. Of these, the S238D variant exhibited a 2.5-fold improvement over the wild-type enzyme in the retroaldol reaction of 2-deoxyribose. Interestingly, this S238D mutant enzyme was shown to accept 3-azidopropinaldehyde as a substrate in a sequential asymmetric aldol reaction to form a deoxy-azidoethyl pyranose, which is a precursor to the corresponding lactone and the cholesterol-lowering agent Lipitor. This azidoaldehyde is not a substrate for the wild-type enzyme. Another structure-based design of new nonphosphorylated substrates was focused on the aldol reaction with inversion in enantioselectivity using the wild type or the S238D variant as the catalyst and 2-methyl-substituted aldehydes as substrates. An example was demonstrated in the asymmetric synthesis of a deoxypyranose as a new effective synthon for the total synthesis of epothilones. In addition, to facilitate the discovery of new enzymatic reactions, the engineered E. coli strain SELECT (Deltaace, adhC, DE3) was developed to be used in the future for selection of DERA variants with novel nonphosphorylated acceptor specificity.
2-脱氧核糖-5-磷酸醛缩酶(DERA,EC 4.1.2.4)催化乙醛与D-甘油醛-3-磷酸之间的可逆醛醇缩合反应,生成D-2-脱氧核糖-5-磷酸。它在醛缩酶中是独特的,因为它催化两种醛的可逆不对称醛醇加成反应。为了扩大DERA的底物范围和立体选择性,人们研究了基于结构的底物设计以及位点特异性突变。以DERA与其天然底物复合物的1.05埃晶体结构为指导,设计了五个定点突变体,以提高其对非天然非磷酸化底物D-2-脱氧核糖的活性。其中,S238D变体在2-脱氧核糖的逆醛醇缩合反应中比野生型酶表现出2.5倍的活性提高。有趣的是,这种S238D突变体酶在顺序不对称醛醇反应中被证明可以接受3-叠氮基丙醛作为底物,形成脱氧叠氮基乙基吡喃糖,这是相应内酯和降胆固醇药物立普妥的前体。这种叠氮醛不是野生型酶的底物。另一种基于结构的新非磷酸化底物设计集中在使用野生型或S238D变体作为催化剂,以2-甲基取代的醛为底物,进行对映选择性反转的醛醇反应。在作为埃博霉素全合成新有效合成子的脱氧吡喃糖的不对称合成中展示了一个例子。此外,为了促进新酶促反应的发现,构建了工程大肠杆菌菌株SELECT(Deltaace,adhC,DE3),以备将来用于筛选具有新型非磷酸化受体特异性的DERA变体。